Parliament’s Trade Committee votes for jobs and access to medicines with a comprehensive SPC Manufacturing Waiver

4 December 2018

The Medicines for Europe Board unanimously applauds last night’s vote […]

Medicines for Europe welcomes Competitiveness Council discussion to stop delocalisation of medicine manufacturing. It is time to effectively position Europe as a global hub for the production of medicines

30 November 2018

Yesterday, 29th November, members of the Competitiveness Council expressed strong […]

Parliament’s Health Committee (ENVI) introduces constructive amendments to SPC Manufacturing waiver vote in its official opinion to the Parliament’s Legal Committee (JURI)

27 November 2018

The introduction of comprehensive SPC manufacturing waiver key to unlocking […]

Health at a Glance Report highlights public value of generic, biosimilar and value added medicines

26 November 2018

The European Commission and OECD – Health at a Glance: […]

Value added medicines: Continuous innovation crucial to improve healthcare across Europe

21 November 2018

The 2nd Value Added Medicines conference gathered a wide range […]

Driving local excellence, delivering European results

5 November 2018

Medicines for Europe is glad to announce the occasion of […]

CJEU decision on Gilead’s SPC on Truvada® leads to successful clarification in English court

20 September 2018

An English Court has determined that the contested supplementary protection […]

SPC manufacturing waiver is good news for Europe

19 September 2018

An SPC manufacturing waiver should be extremely beneficial for Europe […]

SPC manufacturing waiver moves a step closer as influential European Parliament ENVI Committee supports reform

17 September 2018

Medicines for Europe welcomes the European Parliament’s Committee on Environment, […]

Analysis of the proposal for a regulation of a manufacturing exception related to the SPC and aimed to make the European industry competitive

13 September 2018